BioLineRx Ltd. (TLV:BLRX)
1.800
-0.100 (-5.26%)
At close: Nov 27, 2025
BioLineRx Revenue
BioLineRx had revenue of $304.00K USD in the quarter ending June 30, 2025, a decrease of -94.36%. In the year 2024, BioLineRx had annual revenue of $28.94M with 502.92% growth.
Revenue
$28.94M
Revenue Growth
+502.92%
P/S Ratio
1.11
Revenue / Employee
$1.03M
Employees
28
Market Cap
46.99M ILS
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 28.94M | 24.14M | 502.92% |
| Dec 31, 2023 | 4.80M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | - | - | - |
| Dec 31, 2010 | 31.94M | 15.06M | 89.18% |
| Dec 31, 2009 | 16.88M | - | - |
| Dec 31, 2008 | - | - | - |
| Dec 31, 2007 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Teva Pharmaceutical Industries | 55.55B |
| Danel (Adir Yeoshua) | 2.87B |
| Novolog (Pharm-Up 1966) | 2.06B |
| Ilex Medical | 927.57M |
| Kamada | 578.74M |
| SofWave Medical | 255.13M |
| InterCure | 243.12M |
| BrainsWay | 162.56M |
BioLineRx News
- 5 days ago - BioLineRx Ltd. (BLRX) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 5 days ago - BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update - PRNewsWire
- 8 days ago - BioLine Rx's Earnings: A Preview - Benzinga
- 8 days ago - BioLineRx Q3 2025 Earnings Preview - Seeking Alpha
- 11 days ago - BioLineRx to Report Third Quarter 2025 Results on November 24, 2025 - PRNewsWire
- 12 days ago - BioLineRx Announces Receipt of USPTO Notice of Allowance for Key Patent Covering GLIX1 for Treating a Broad Range of Cancer Types - PRNewsWire
- 2 months ago - BioLineRx Ltd. (BLRX) Investor Call (Transcript) - Seeking Alpha
- 2 months ago - BioLineRx Ltd. - Special Call - Seeking Alpha